Embodiments relate to a method and apparatus for stimulating the production of extracellular vesicles (EVs) from a population of cells. Some embodiments relate to a method for stimulating the production of extracellular vesicles (EVs) from a population of cells, the method comprising: (i) exposing a culture media comprising the population of cells to acoustic wave energy and (ii) harvesting the EVs produced from the population of cells following the exposure. Some embodiments relate to an apparatus for use in stimulating the production of EVs from a population of cells, the apparatus comprising: (i) an acoustic wave generator configured to generate acoustic energy at a selected power and frequency; and (ii) a receptacle for accommodating a population of cells in a culture media, the receptacle being configured to receive acoustic energy generated by the acoustic wave generator.

Disclosed are compositions comprising chimeric antigen receptors (CARs) and related methods of use in cancer immunotherapy. Compositions include reprogrammed immune cells (e.g., macrophages, neutrophils, dendritic cells, and T cells) that are metabolically fit for tumor microenvironments. The engineered immune cells are reprogrammed to express one or more of recombinant CARs at their cell surfaces and are loaded with glycolysis accelerating metabolites (e.g., F16BP or succinate). Methods of treating a subject with a condition, such as cancer, are also disclosed and include administering an effective amount of a composition comprising an engineered immune cell to a subject in need thereof.

Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.

Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

The present invention pertains to extracellular vesicles (EVs), wherein the EVs comprise domains present on the surface of the EV, which modify the circulation time of such EVs. Such EVs display improved pharmacokinetics and are therefore useful as therapeutics. Such EVs may also be useful for affinity purification of the EV drug substance.

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

The present invention relates to prevention and/or treatment of infection by a platelet-targeting microbe in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating (and/or related uses) infection by a platelet-targeting microbe in a subject, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, b) an outer surface comprising a cellular membrane derived from a platelet; and optionally c) an agent for preventing said infection, treating said infection, diagnosing said infection, prognosing said infection and/or monitoring prevention or treatment of said infection. Exemplary platelet-targeting infections include infections by a bacterium, a virus, a fungus and/or a parasite.

Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.